Hans‐Peter Gerber

27.8k total citations · 9 hit papers
91 papers, 21.1k citations indexed

About

Hans‐Peter Gerber is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hans‐Peter Gerber has authored 91 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 45 papers in Molecular Biology and 33 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hans‐Peter Gerber's work include Angiogenesis and VEGF in Cancer (31 papers), Monoclonal and Polyclonal Antibodies Research (31 papers) and HER2/EGFR in Cancer Research (23 papers). Hans‐Peter Gerber is often cited by papers focused on Angiogenesis and VEGF in Cancer (31 papers), Monoclonal and Polyclonal Antibodies Research (31 papers) and HER2/EGFR in Cancer Research (23 papers). Hans‐Peter Gerber collaborates with scholars based in United States, Switzerland and France. Hans‐Peter Gerber's co-authors include Napoleone Ferrara, Jennifer LeCouter, Kenneth J. Hillan, William Novotny, Vishva M. Dixit, Ajay K. Malik, Xiao Liang, Fabrizio Condorelli, Jeanie Park and Joe Kowalski and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Hans‐Peter Gerber

89 papers receiving 20.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The biology of VEGF and its receptors

2003 7.6k citations Napoleone Ferrara, Hans‐Peter Gerber et al. Nature Medicine profile →
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

2004 2.0k citations Napoleone Ferrara, Kenneth J. Hillan et al. Nature Reviews Drug Discovery profile →
Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells

1998 782 citations Hans‐Peter Gerber, Napoleone Ferrara et al. profile →
VEGF is required for growth and survival in neonatal mice

1999 727 citations Hans‐Peter Gerber, Kenneth J. Hillan et al. profile →
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

2007 673 citations Farbod Shojaei, Ajay K. Malik et al. profile →
Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes

1997 642 citations Hans‐Peter Gerber, Napoleone Ferrara et al. profile →
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

2002 567 citations Hans‐Peter Gerber, Ajay K. Malik et al. profile →
Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1

2003 513 citations Jennifer LeCouter, Hans‐Peter Gerber et al. profile →
Transcriptional Activation Modulated by Homopolymeric Glutamine and Proline Stretches

1994 510 citations Hans‐Peter Gerber, Katja Seipel et al. profile →

Peers

Countries citing papers authored by Hans‐Peter Gerber

Since Specialization

Citations

This map shows the geographic impact of Hans‐Peter Gerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Peter Gerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Peter Gerber more than expected).

Fields of papers citing papers by Hans‐Peter Gerber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Peter Gerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Peter Gerber. The network helps show where Hans‐Peter Gerber may publish in the future.

Co-authorship network of co-authors of Hans‐Peter Gerber

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Peter Gerber. A scholar is included among the top collaborators of Hans‐Peter Gerber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Peter Gerber. Hans‐Peter Gerber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death 2025 ·Molecular Cancer Therapeutics ·Robert Yuan, Andrew McGeehan, Sihong Zhou, Christine Cheng, Mark Armanini, Jennifer Smith, Millicent Embry, Rhoneil Pena, Danielle K. Lewis, Genevive Hernandez, Krishna Bajjuri, Cuong Tran, Gang Yin, Cristina L. Abrahams, (unknown), Hans‐Peter Gerber, Alice Yam, Helena Kiefel	1
2	Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1) 2017 ·Molecular Cancer Therapeutics ·Matthew Sung, Xingzhi Tan, Bingwen Lu, Jonathan Golas, Christine Hosselet, Fang Wang, Laurie Tylaska, Lindsay King, Dahui Zhou, Russell G. Dushin, Jeremy S. Myers, Edward Rosfjord, Judy Lucas, Hans‐Peter Gerber, Frank Loganzo	155
3	Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients 2017 ·PLoS ONE ·Steven Pirie‐Shepherd, Cory L. Painter, Pamela Whalen, (unknown), Marc D. Roy, (unknown), (unknown), (unknown), (unknown), Shibing Deng, Wenyan Zhong, (unknown), Dena Marrinucci, Hans‐Peter Gerber, Eric L. Powell	7
4	Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring 2016 ·Clinical Cancer Research ·Magali Guffroy, Hadi Falahatpisheh, (unknown), John M. Kreeger, Leslie Obert, Karen Walters, Richard A. Goldstein, (unknown), Timothy Coskran, William J. Reagan, Danielle Sullivan, Chunli Huang, Sharon Sokolowski, (unknown), Hans‐Peter Gerber, Martín Finkelstein, Nasir Khan	47
5	Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies 2014 ·Molecular Immunology ·Boris Shor, Hans‐Peter Gerber, Puja Sapra	99
6	Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells 2012 ·Molecular Cancer Therapeutics ·Puja Sapra, Marc Damelin, John F. DiJoseph, Kimberly Marquette, Kenneth G. Geles, Jonathon Golas, Maureen Dougher, (unknown), Andreas Giannakou, Kiran Khandke, Russell G. Dushin, Elana Ernstoff, Judy Lucas, Mauricio Leal, (unknown), Christopher J. O’Donnell, Lioudmila Tchistiakova, Robert T. Abraham, Hans‐Peter Gerber	51
7	Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis 2009 ·The Journal of Immunology ·Ezogelin Oflazoglu, Tamar E. Boursalian, Weiping Zeng, Ana C. Edwards, (unknown), Julie A. McEarchern, Che‐Leung Law, Hans‐Peter Gerber, Iqbal S. Grewal	47
8	Antibody drug-conjugates targeting the tumor vasculature 2009 ·mAbs ·Hans‐Peter Gerber, Peter D. Senter, Iqbal S. Grewal	58
9	Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index 2008 ·Molecular Cancer Therapeutics ·Charlotte F. McDonagh, Kristine M. Kim, Eileen Turcott, Lindsay L. Brown, Lori Westendorf, Tiffany Feist, Django Sussman, Ivan J. Stone, Martha E. Anderson, Jamie B. Miyamoto, Robert P. Lyon, Stephen C. Alley, Hans‐Peter Gerber, Paul J. Carter	60
10	Anti-CD30 diabody-drug conjugates with potent antitumor activity 2008 ·Molecular Cancer Therapeutics ·Kristine M. Kim, Charlotte F. McDonagh, Lori Westendorf, Lindsay L. Brown, Django Sussman, Tiffany Feist, Robert P. Lyon, Stephen C. Alley, Nicole M. Okeley, Xinqun Zhang, Melissa C. Thompson, Ivan J. Stone, Hans‐Peter Gerber, Paul J. Carter	73
11	Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies 2007 ·Molecular Cancer Therapeutics ·Hans‐Peter Gerber, (unknown), Ivan J. Stone, Mechthild Jonas, (unknown), Jamie B. Miyamoto, Lindsay L. Brown, Lori Westendorf, Damon L. Meyer, Django Sussman, Paul Carter, Che‐Leung Law, Iqbal S. Grewal	2
12	Tumor refractoriness to anti-VEGF treatment mediated by CD11b+Gr1+ myeloid cells 2007 ·Molecular Cancer Therapeutics ·Farbod Shojaei, Xiumin Wu, Ajay K. Malik, Cuiling Zhong, Megan E. Baldwin, Stefanie Schanz, Germaine Fuh, Hans‐Peter Gerber, Napoleone Ferrara	1
13	Epithelial–vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis 2007 ·Developmental Biology ·Hiroaki Yamamoto, (unknown), Hans‐Peter Gerber, Napoleone Ferrara, Jeffrey A. Whitsett, Thiennu H. Vu	116
14	Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma 2006 ·Clinical Cancer Research ·Max L. Tejada, Lanlan Yu, Jianying Dong, Kenneth Jung, Gloria Meng, Franklin Peale, Gretchen Frantz, (unknown), Xiao‐Huan Liang, Hans‐Peter Gerber, Napoleone Ferrara	94
15	Generation of mice carrying floxed VEGFR-1 and VEGFR-2 alleles to study the effects of postnatal gene ablation on angiogenesis and hematopoiesis 2004 ·Cancer Research ·Megan E. Baldwin, Xiao Huan Liang, (unknown), Johanna Busch, Zhenyu Gu, Meron Roose-Girma, Christine Olsson, Sharon Erickson, Napoleone Ferrara, Hans‐Peter Gerber	1
16	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer breakdown → 2004 ·Nature Reviews Drug Discovery ·Napoleone Ferrara, Kenneth J. Hillan, Hans‐Peter Gerber, William Novotny	2007
17	The biology of VEGF and its receptors breakdown → 2003 ·Nature Medicine ·Napoleone Ferrara, Hans‐Peter Gerber, Jennifer LeCouter	7641
18	VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis 2002 ·Cancer Cell ·Masahiro Inoue, Jeffrey H. Hager, Napoleone Ferrara, Hans‐Peter Gerber, Douglas Hanahan	306
19	Basal components of the transcription apparatus (RNA polymerase II, TATA ‐binding protein) contain activation domains: Is the repetitive c‐terminal domain (CTD) of RNA polymerase II a “Portable Enhance Domain”? 1994 ·Molecular Reproduction and Development ·Katja Seipel, Oleg Georgiev, Hans‐Peter Gerber, (unknown)	19
20	[Prevention of dextran-induced anaphylactoid reactions by preinjection of 20 ml hapten in 12 000 patients in Switzerland]. 1982 ·PubMed ·(unknown), (unknown), (unknown), Hans‐Peter Gerber, H. Laubenthal, K. Meßmer	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact